Dynamics of antibody titers to SARS-CoV-2 and clinical outcomes after sotrovimab pre-exposure prophylaxis early after allogeneic hematopoietic stem cell transplantation - Top-Institutions - MDSpire

Dynamics of antibody titers to SARS-CoV-2 and clinical outcomes after sotrovimab pre-exposure prophylaxis early after allogeneic hematopoietic stem cell transplantation

  • By

  • Gioele Capoferri

  • Carla Simone Walti

  • Pascal Urwyler

  • Silvio Ragozzino

  • Jakob R. Passweg

  • Jörg Halter

  • Manuel Battegay

  • Veronika Baettig

  • Maja Weisser

  • Brice Arnold

  • Benedict Morin

  • Yukino Guetlin

  • Diana Albertos Torres

  • Güliz Tuba Barut

  • Volker Thiel

  • Adrian Egli

  • Beatrice Drexler

  • Nina Khanna

  • February 16, 2023

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Infectious Diseases
    • Immunology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Infectious Diseases

  • #3

    University Hospital Basel
    University Hospital Basel

    Basel, Switzerland

    Key Differentiators

    • Hematology
    • Infectious Diseases
    • Clinical Virology

  • #4

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Infectious Diseases
    • Immunology

  • #5

    National Institutes of Health (NIH) - National Cancer Institute
    National Institutes of Health (NIH) - National Cancer Institute

    Bethesda, MD

    Key Differentiators

    • Hematology
    • Immunology
    • Infectious Diseases

Original Source(s)

Dynamics of antibody titers to SARS-CoV-2 and clinical outcomes after sotrovimab pre-exposure prophylaxis early after allogeneic hematopoietic stem cell transplantation

  • by Gioele Capoferri, Carla Simone Walti, Pascal Urwyler, Silvio Ragozzino, Jakob R. Passweg, Jörg Halter, Manuel Battegay, Veronika Baettig, Maja Weisser, Brice Arnold, Benedict Morin, Yukino Guetlin, Diana Albertos Torres, Güliz Tuba Barut, Volker Thiel, Adrian Egli, Beatrice Drexler, Nina Khanna

  • February 16, 2023

Related Content

Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study

COVID-19-Associated Mucormycosis: Identifying Mortality Predictors in a Retrospective Cohort Study

Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies